Drug Profile

BX 004

Alternative Names: BX-004; BX004-A

Latest Information Update: 11 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BiomX
Class Antibacterials; Bacteriophages
Mechanism of Action Cell death stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pseudomonal infections
New Molecular Entity No

Highest Development Phases

Phase II Pseudomonal infections
Preclinical Bronchiectasis

Most Recent Events

08 Dec 2025 BiomX terminates a phase IIb trial in Pseudomonal infections in USA (Inhalation), following internal analysis and DMC feedback (NCT06998043)
17 Oct 2025 BiomX addresses the FDA’s queries related to the third-party nebulizer used to deliver BX004. An additional FDA request for limited technical clarifications on the nebulizer has been addressed
17 Oct 2025 BiomX plans a phase III trial for cystic fibrosis

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com